A Phase 2/3 interventional study of TP-03, 0.25% and TP-03 Vehicle in Blepharitis, sponsored by Tarsus Pharmaceuticals, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-21.
Sponsored by Tarsus Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Blepharitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Blepharitis · United States.
Among the 39 studies in Blepharitis with a site in United States, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 2/3, and was the 26th registered.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
Browse Blepharitis studies →5 of the 39 studies in Blepharitis with a site in United States are open now. Recruiting first, the newest first:
Brent Kramer · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Olympic Ophthalmics, Inc. · Sites in United States
Ages 18+
University of Notre Dame · Sites in United States
Ages 18+ · Healthy volunteers
Brent Kramer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Blepharitis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 5 · Phase 4 11
First in 2001; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 421 is above the median of 60 across 65 interventional studies indexed under Blepharitis.
Median enrollment 60 across the 37 interventional studies, 330 across the 2 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 39 have an industry lead sponsor. The 10 most frequent:
Tarsus Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Tarsus Pharmaceuticals, Inc. has 5 studies filed under Blepharitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Blepharitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07856680Brent KramerClinical Lid Eradication of Antifungal-Responsive FUNGUS Study | 2027-03 |
| NCT07869498Brent KramerOcular Dysbiosis in Eyelid Disease | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 39 studies in Blepharitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.
This Phase 2b/3 study is a randomized, controlled, multicenter, double-masked, parallel trial to compare the safety and efficacy of TP-03, 0.25%, to vehicle control for the treatment of Demodex blepharitis. The primary objective of the study is to assess the safety and efficacy of TP-03 compared to its vehicle from Day 1 to Day 43 in adult participants with mild to severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp biomicroscopy and dilated ophthalmoscopy findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
Drug: TP-03, 0.25%
Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days
Drug: TP-03 Vehicle
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Also known as: Lotilaner ophthalmic solution, 0.25%
Vehicle of TP-03 ophthalmic solution, administered twice a day
Proportion of Participants Cured Based on a Collarette Score at Day 43.
The proportion of participants cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
Time frame: 43 days
The Proportion of Participants With Eradication of Demodex Mites in the Analysis Eye at Day 43
The proportion of participants with Demodex mites eradicated at Day 43 where eradication is defined as a mite density of 0 mites/lash for the analysis eye. The mite density is obtained by epilating four of more lashes and dividing the number of mites observed under the microscope by the number of lashes. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
Time frame: 43 days
Proportion of Participants Cured Based on a Composite Collarette and Erythema Score of 0 in the Analysis Eye at Day 43.
The proportion of participants cured where cure is defined as a composite of the collarettes, 0-2 lashes with collarettes on the upper eyelid of the analysis eye, and normal lid margin erythema for the upper eyelid of the analysis eye at Day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
Time frame: 43 days
| Milestone | Active | Control |
|---|---|---|
| Started | 212 | 209 |
| Completed | 208 | 203 |
| Not completed | 4 | 6 |
The proportion of participants cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
| Proportion cured | Active | Control |
|---|---|---|
| Proportion of Participants Cured Based on a Collarette Score at Day 43. | 0.439 ± 0.034 | 0.072 ± 0.018 |
The proportion of participants with Demodex mites eradicated at Day 43 where eradication is defined as a mite density of 0 mites/lash for the analysis eye. The mite density is obtained by epilating four of more lashes and dividing the number of mites observed under the microscope by the number of lashes. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values
| Proportion eradicated | Active | Control |
|---|---|---|
| The Proportion of Participants With Eradication of Demodex Mites in the Analysis Eye at Day 43 | 0.677 ± 0.032 | 0.173 ± 0.026 |
The proportion of participants cured where cure is defined as a composite of the collarettes, 0-2 lashes with collarettes on the upper eyelid of the analysis eye, and normal lid margin erythema for the upper eyelid of the analysis eye at Day 43. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.
| Proportion cured | Active | Control |
|---|---|---|
| Proportion of Participants Cured Based on a Composite Collarette and Erythema Score of 0 in the Analysis Eye at Day 43. | 0.139 ± 0.024 | 0.01 ± 0.007 |
Collected over 57 days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | 0/212 (0%) | 3/212 (1.4%) | 37/212 (17.5%) |
| Control | 0/209 (0%) | 1/209 (0.5%) | 39/209 (18.7%) |
| Event | Active | Control |
|---|---|---|
| Vascular access site pseudoaneurysmInjury, poisoning and procedural complications | 0/212 | 1/209 |
| COVID-19Infections and infestations | 1/212 | 0/209 |
| PneumoniaInfections and infestations | 1/212 | 0/209 |
| HaematuriaRenal and urinary disorders | 1/212 | 0/209 |
| Event | Active | Control |
|---|---|---|
| Instillation site painGeneral disorders | 25/212 | 16/209 |
| Instillation site pruritusGeneral disorders | 3/212 | 7/209 |
| Visual acuity reducedEye disorders | 6/212 | 6/209 |
| Eye painEye disorders | 3/212 | 3/209 |
| ChalazionEye disorders | 1/212 | 3/209 |
| Eye dischargeEye disorders | 3/212 | 2/209 |
| Vision blurredEye disorders | 2/212 | 2/209 |
| Eye pruritusEye disorders | 1/212 | 2/209 |
| Swelling of eyelidEye disorders | 1/212 | 2/209 |
| Age, Categorical(Participants) | Active | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 86 | 65 | 151 |
| >=65 years | 126 | 144 | 270 |
| Age, Continuous(years) | Active | Control | Total |
|---|---|---|---|
| Mean | 66.1 ± 12.09 | 67.8 ± 12.63 | 67.0 ± 12.37 |
| Sex: Female, Male(Participants) | Active | Control | Total |
|---|---|---|---|
| Female | 123 | 117 | 240 |
| Male | 89 | 92 | 181 |
| Ethnicity (NIH/OMB)(Participants) | Active | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 11 | 25 |
| Not Hispanic or Latino | 198 | 198 | 396 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 16 | 27 |
| White | 195 | 187 | 382 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Active | Control | Total |
|---|---|---|---|
| United States | 212 | 209 | 421 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in May 2021, 7 months.
Results were first posted in Dec 2023, 2 years 7 months after primary completion. A results delay was requested in Apr 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TP-03
Tarsus Pharmaceuticals, Inc.